Tim M. Mayleben
2020 - Esperion Therapeutics
In 2020, Tim M. Mayleben earned a total compensation of $6.9M as Former Chief Executive Officer at Esperion Therapeutics, a 541% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $210,000 |
|---|---|
| Option Awards | $4,518,084 |
| Salary | $700,000 |
| Stock Awards | $1,420,021 |
| Other | $76,919 |
| Total | $6,925,024 |
Mayleben received $4.5M in option awards, accounting for 65% of the total pay in 2020.
Mayleben also received $210K in non-equity incentive plan, $700K in salary, $1.4M in stock awards and $76.9K in other compensation.
Rankings
In 2020, Tim M. Mayleben's compensation ranked 1,412th out of 13,090 executives tracked by ExecPay. In other words, Mayleben earned more than 89.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,412 out of 13,090 | 89th |
Division Manufacturing | 520 out of 5,620 | 91st |
Major group Chemicals And Allied Products | 185 out of 2,253 | 92nd |
Industry group Drugs | 156 out of 1,953 | 92nd |
Industry Pharmaceutical Preparations | 110 out of 1,458 | 93rd |
Source: SEC filing on April 14, 2022.
Mayleben's colleagues
We found three more compensation records of executives who worked with Tim M. Mayleben at Esperion Therapeutics in 2020.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019